Downloads
Abstract
Objective: Evaluating the efficacy of preoperative chemoradiotherapyand relating factors in patients with T3, T4, non - distant metastatic rectal cancer.
Methods: Thirty - seven patients with T3, T4, no metastasis rectal cancer were treated with radiotherapy (45 Gy/25 fractions) and concomitant Capecitabine (825 mg/m2 bid on each day of the radiotherapy period) at Hue Central Hospital between February 2019 and July 2021. All patients were evaluated for response to the treatment using RECIST 1.1 and toxicities according to CTCAE v5.0.
Results: The mean age was 56.6 ± 12.5 years; with male:female ratio of 2.4:1. The most common symptom was hematochezia (86.5%). The majority of tumors were stage 4 (62.5%) and were located in distal rectum (56.8%). There were 70.3% patients with T3 and 59.5% with positive node. The proportion of stage II and III were 40.5% and 59.5%, respectively. Adenocarcinoma accounted mostly for 97.3%. After neoadjuvant treatment, tumor downstaging rate were 48.6% and nodal downstaging rate were 48.6%. Overall clinical response and complete clinical response rates were achieved by 51.3% and 16.2% of the patients, respectively. There was a correlation of overall response rate after treatment with sex, location and stage of tumor. No patient had grade 4 toxicity. Grade 3 toxicity occurred in only one patient (2.7%) with anemia, the remaining were grade 1 and 2 toxicities which took dominate rate.
Conclusion: Preoperative chemoradiotherapy in T3, T4, no metastasis rectal cancer is an effective and safe treatment with an acceptable toxicity profile.
References
Global Cancer Observation. Cancer Today, International Agency for Research on Cancer. Available at https://gco. iarc.fr/today. [Accessed 25 November 2021]. 2020.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006;17:246-51.
Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol. 2008;184:450-6.
Phạm Cẩm Phương, Mai Trọng Khoa. Đánh giá mức độ thoái triển u sau hóa xạ trị trước mổ bệnh ung thư trực tràng thấp giai đoạn tiến triển tại chỗ. Tạp chí Ung thư học Việt Nam. 2013;2:84-88.
Huỳnh Thanh Hải, Phạm Nguyên Tường. Đánh giá hiệu quả xạ trị tiền phẫu liệu trình ngắn trong điều trị ung thư trực tràng. Tạp chí Ung thư học Việt Nam. 2019;1:396- 400.
Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63:346-53.
Trương Thu Hiền, Nguyễn Văn Ba, Phạm Văn Thái, Dương Thùy Linh, Trần Văn Tôn. Đánh giá hiệu quả hóa xạ trị đồng thời trước phẫu thuật điều trị ung thư trực tràng giai đoạn II, III. Tạp chí Y học Việt Nam. 2021;501:4-7.
Nguyễn Văn Hiếu, Lê Văn Quảng, Bùi Công Toàn. Đánh giá kết quả hóa xạ trị tiền phẫu trong ung thư trực tràng giai đoạn xâm lấn. Tạp chí Khoa học và Công nghệ. 2018;60:3-6.
| Published | 27-07-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.2 | |
| Keywords | Ung thư trực tràng, hóa xạ trị tiền phẫu Rectal cancer, preoperative chemoradiotherapy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital